XML 31 R2.htm IDEA: XBRL DOCUMENT v3.2.0.727
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2015
Dec. 31, 2014
Current assets:    
Cash and cash equivalents $ 70,297,574 $ 40,543,982
Short-term investments 84,295,821 53,075,974
Accounts receivable 5,608,845 2,804,207
Prepaid expenses and other current assets 551,298 797,973
Prepaid expenses and other current assets from affiliated entity 1,045,370 1,382,375
Deferred tax asset 342,573 342,573
Total current assets 162,141,481 98,947,084
Fixed assets, net 5,497,203 4,583,204
Investment in affiliated entity 18,849,647 12,340,811
Intangible assets, net 4,333,444 4,776,059
Goodwill 10,113,371 10,113,371
Common stock warrants 186,500 550,000
Other assets 581,342 474,568
Total assets 201,702,988 131,785,097
Current liabilities:    
Accounts payable and accrued expenses 6,068,232 6,383,170
Accounts payable and accrued expenses due to affiliated entity 3,417,017 28,407
Accrued clinical trial expenses 2,546,487 2,007,432
Common stock warrants 1,710,229 2,022,729
Deferred revenue 152,108 3,187,223
Deferred revenue from affiliated entity 432,291 394,791
Deferred rent 193,442 0
Total current liabilities 14,519,806 14,023,752
Deferred revenue, net of current portion 313,667 173,779
Deferred revenue from affiliated entity, net of current portion 649,194 836,694
Deferred rent, net of current portion 4,758,564 4,709,229
Deferred tax liabilities 504,049 504,049
Total liabilities 20,745,280 20,247,503
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Common stock 71,810 60,741
Additional paid-in capital 529,555,022 443,327,915
Accumulated deficit (348,740,319) (331,910,290)
Accumulated other comprehensive loss (324,192) (251,390)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 180,562,321 111,226,976
Non-controlling interest 395,387 310,618
Total stockholders’ equity 180,957,708 111,537,594
Total liabilities and stockholders’ equity $ 201,702,988 $ 131,785,097